Security Snapshot

Eloxx Pharmaceuticals, Inc. - Common Stock, $0.01 par value per share Institutional Ownership

CUSIP: 29014R301

13F Institutional Holders and Ownership History

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Shares outstanding
4,277,004

Key facts

  • 29014R301 - Eloxx Pharmaceuticals, Inc. - Common Stock, $0.01 par value per share is tracked under CUSIP 29014R301.
  • Latest finished 13F holder period is not available.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Quarterly ownership records are not available yet for this CUSIP.
  • This page updates as SEC-backed holdings history becomes available.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

29014R301

Latest holder period

n/a

13F holders

13D/G owners

4

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
4
Security
29014R301
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Domicilium Real Estate Fund III LP 20% +302% 854,973 +3542% Domicilium Capital Partners LLC 05 Jun 2026
Invus Global Management, LLC 10% 403,586 Raymond Debbane 09 Jun 2026
EcoR1 Capital, LLC 9.9% 403,586 EcoR1 Capital, LLC 09 Jun 2026
Stonepine Capital Management, LLC 9.9% 403,228 Stonepine Capital Management, LLC 09 Jun 2026
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .